Gensia votes for its sales force

Marketing decisions can depend on what indications a company chooses to develop first. One indication may make it wise to co-market, while another may enable a company to retain exclusive rights. The decision by Gensia Pharmaceuticals Inc. to retain exclusive marketing rights to Arasine provides a case in point.

GNSA last week said it will market the drug itself, rather than co-promote it with partner Marion Merrell Dow. GNSA has applied for marketing approval for Arasine to prevent adverse events in coronary artery bypass surgery in the U.S., Canada and Europe.